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Introduction 39
The emergence of KPC-2 class-A Beta-Lactamase (BL) carbapenemase, which confers resistance to last 40 resort carbapenems, poses a serious health threat to the public. KPC-2, a class A BL, uses a catalytic 41 serine to hydrolyze the β-lactam ring. Specifically, the hydrolysis reaction proceeds through a series of 42 steps involving: (i) the formation of a precovalent complex, (ii) the conversion to a high-energy 43 tetrahedral acylation intermediate, (iii) followed by a low-energy acyl-enzyme complex, (iv) a high-44
energy tetrahedral de-acylation intermediate consequent to catalytic water attack, and (v) finally the 45 release of the hydrolyzed β-lactam ring product from the enzyme. [1] [2] [3] [4] [5] [6] . 46
Notably to treat infections caused by bacteria that produce class A BLs, mechanism-based inhibitors 47 (i.e., clavulanic acid, sulbactam, and tazobactam) are administered in combination with β-lactam 48 antibiotics. However, strains harboring KPC-type β-lactamases are reported to be resistant to available 49 β-lactamase inhibitors. Moreover, because of KPC-2's broad spectrum of activity (which includes 50 penicillins, cephalosporins, and carbapenems) treatment options against KPC-2-producing bacteria are 51 scarce, and "last-resort" carbapenems are ineffective as well [7] . Therefore, studies directed to the 52 discovery of novel, non β-lactam KPC-2 inhibitors have multiplied in the last years. Recently, new drugs 53 able to restore susceptibility to β-lactams i.e. the novel inhibitor avibactam in combination with 54 ceftazidime (CAZ) and RPX7009 (vaborbactam) with meropenem have been approved ( Fig. 1 As attention on KPC-2 rises, the number of crystal structures of its apo and complexed form disclosed 56 in the PDB has increased, making KPC-2 a druggable target for structure based drug design efforts and 57 for the study of novel, non β-lactam like inhibitors of this threatening carbapenemase [9] [10] [11] [12] Left: binding mode of hydrolyzed cefotaxime (PDB code 5UJ3). Right: binding mode of hydrolyzed faropenem (PDB code 5UJ4). The second rotamer of Trp105 adopted in the apo-enzyme is coloured in beige, protein side chains in blue and ligands in green. Hydrogen bonds are indicated as black dots.
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Both ligands form hydrogen-bond interactions with their C4-carboxyl group to Ser130, Thr235 and 62
Thr237. The dihydrothiazine moiety of cefotaxime and the dihydrothiazole moiety of faropenem forms 63 π-π-stacking interactions with Trp105. In the apo-enzyme, this side chain adopts two rotamers, upon 64 binding of a ligand just one. Mutagenesis studies have shown the importance of Trp105 in substrate 65 recognition [7] . The faropenem ring nitrogen forms a hydrogen-bond interaction with Ser130, whereas 66 the ring nitrogen of cefotaxime a hydrogen bond with Ser70. The aminothiazole ring of cefotaxime 67 forms van-der-Waals contacts with Leu167, Asn170, Cys238 and Gly239, while the oxyimino group 68 and the hydroxyethyl group of faropenem are solvent exposed (Fig. 2 
).[13] 69
Based on this and other structural information, we used a hierarchical screening cascade for the 70 discovery of non β-lactam like KPC-2 inhibitors. The selected candidates were then validated as hits 71 against isolated recombinant KPC-2. Among the tested compounds 9a, a benzotiazole derivative, and 72 11a, a tetrazole-containing inhibitor, showed the highest activity against KPC-2 and behaved as 73 competitive inhibitors of the targeted carbapenemase ( Fig. 1 ). Compound 11a was subsequently directed 74 to chemical optimization to improve potency vs the enzyme and explore structural requirement for 75 inhibition in KPC-2 binding site. Further, the compounds were evaluated against clinical strains 76 overexpressing KPC-2 and the most promising compound reduced the MIC of the β-lactam antibiotic 77 meropenem by four fold. 78
79

Materials and Methods
80
Pharmacophore hypothesis 81
A search for similar binding sites of KPC-2 was carried out using the online tool PoSSuM -Search K 82 [15, 16] . Based on shared ligand interactions in the retrieved structures (Table 1) , a pharmacophore was 83 defined based on a K. pneumoniae KPC-2 protein structure (PDB code 3RXW) [17] and the ligand OJ6 84 of CTX-M-9 β-lactamase (PDB code 4DE1) [18] . The derived pharmacophore contained a hydrogen-85 6 bond acceptor feature for interaction with Thr237, Thr235 and Ser130, a hydrophobic feature for π-86 stacking with Trp105 and a hydrogen bond acceptor feature for interactions with Asn132 ( Fig. 3) . 87 88 89 
Virtual Screening
93
Our in-house MySQL-database of commercially available compounds was filtered for compounds 94 fulfilling the following lead-like criteria: between 10 ten and 25 twenty-five heavy atoms, between one 95 and six hydrogen-bond acceptors, between one and three hydrogen-bond donors and a clog P between -96 3 and 3. In addition, the complexity was limited by only including compounds with less than 7 rotatable 97 bonds and between 1 and 3 ring systems. Compounds containing unwanted reactive or toxic functional 98 groups were excluded as well [23] . 99
In-house python scripts based on OpenEye's OEChem toolkit (OEChem, version 2016.6.1, OpenEye 100
Scientific Software, Inc., Santa Fe, NM, USA) were used to charge, tautomerize and stereoisomerize 101 the selected compounds. Conformers were generated using OpenEye's OMEGA toolkit [24] . The 102 pharmacophore filtering was carried out using Molecular Operating Environment (MOE, Chemical 103
Computing Group). Compounds that passed the pharmacophore filter were transformed into a format 104 suitable for docking as described previously [25] . 105
The crystal structure of K. pneumoniae KPC-2 (PDB code 3RXW) [17] was used as receptor for 106 docking. The 'protonate 3D' tool of MOE was used to add polar hydrogen atoms to the receptor, energy 107 minimize their positions and to assign partial charges based on the AMBER force field parameters. 108
Water molecules and ligands (CIT and SR3) were deleted and the position of the Ser69 side chain was 109 energy minimized with the same force field parameters. The structure was aligned with the crystal 110 structure of E.coli CTX-M-9 (PDB code 4DE1) and the ligand 0J6 was used to define spheres as 111 matching points for docking. Grid-based excluded volume, van-der-Waals potential and electrostatic 112 potential as well as solvent occlusion maps were calculated as described earlier [26, 27] . 113
The compounds were docked into the binding site of KPC-2 using DOCK3.6 [27] [28] [29] . Parameters for 114 sampling ligand orientations were set as follows: bin size of ligand and receptor were set to 0.4 Å, 115 overlap bins were set to 0.2 Å and the distance tolerance for receptor and ligand matching spheres was 116 8 set to 1.5 Å. Each docking pose which did not overlap with the receptor was scored for electrostatic and 117 van-der-Waals complementarity and penalized according to its estimated partial desolvation energy. For 118 each compound, only the best-scoring pose out of its tautomers, protonation states or ring alignments 119 was saved in the final docking hit list. The docking hit list was filtered with the pharmacophore described Reactions were monitored using a Beckmann DU640® spectrophotometer at 405nM for CENTA and 143 480 nM wavelength for nitrocefin [35] . The test compounds were synthesized as described below or 144 purchased from Enamine, TimTec, Vitas-M, ChemBridge, Otava, Life Chemicals or Apollo Scientific 145 and assayed without further purification. Compounds were dissolved in dimethyl sulfoxide (DMSO) to 146 a concentration of 25 mM and stored at -20°C. The highest concentration at which the compounds were 147 tested was up to 1 mM (depending on their solubility). All experiments were performed in duplicate and 148 the error never exceeded 5%. The reaction was typically initiated by adding KPC-2 to the reaction buffer 149 last. To control for incubation effects, protein was added to the reaction buffer first, and the reaction 150 was initiated by the addition of reporter substrate after 10 minutes of enzyme-compound incubation. 151
The results are reported in Tables 2 and Table 3 . 152
Competitive inhibition mechanism and the Ki for compound 9a was determined by Lineweaver-Burk 153 times. In one structure, both rotamers were present (Fig.4) . Thus, for virtual screening, the structure with 219 the highest resolution was selected (K. pneumoniae KPC-2 in complex with the covalent inhibitor 220 penamsulfone PSR-3-226 (PDB code 3RXW), 1.26 Å resolution). This structure contained both 221 rotamers of Trp105. For virtual screening, the closed conformation was chosen, as this is the most 222 dominant conformation upon ligand binding. 223 
224
Only little diversity with respect to bound ligands was found in the KpKPC2 structures. To obtain a 225 more detailed picture on key interactions and to derive a pharmacophore hypothesis, PoSSuM -Search 226 K was used to search for similar binding sites containing non-covalent ligands. This resulted in thirteen 227 structures (Table 1) , all having tetrazoles or carboxylates derivatives bound in the hydrophilic pocket 228 formed by the amino acids corresponding to Thr235, Thr237, Ser130 and Ser70 in KpKPC2 (Fig.4) . 229
Seven of the contained ligands were fragment hits for E.coli CTX-M class A extended spectrum β-230 lactamase (ESBL), and four were derivatives of the most potent screening hit. Further, a structure of S. 
238
Based on the retrieved structures, a pharmacophore hypothesis was derived. All of the ligands in these 239 structures as well as the β-lactamase binding protein (PDB code 3E2L, 3E2K) and the covalent ligand 240 of the structure used as receptor, formed a hydrogen-bond with Thr235 or Thr237. Accordingly, a 241 hydrogen-bond acceptor at the corresponding ligand position was considered to be crucial for binding 242 (Fig. 3) . Further, in most of the structures the ligands formed interactions with Trp105 (Ambler 243 numbering) [22] . Therefore, this interaction was also included in the pharmacophore hypothesis. 244
Hydrogen-bond interactions to Asn130 were found in four structures (PDB codes 3RXW, 3G32, 3G30, 245 4EUZ) and included as well. 246 247 A hierarchical approach was adopted for virtual screening. First, our in-house database of around five 248 million purchasable compounds was filtered for lead-like molecules [23]. In the second step, the 249 obtained hits were screened with the above-described pharmacophore resulting in 44658 compounds. 250
Out of these, 31122 compounds could be docked into the Kp KPC2 binding site. Filtering these binding 251 14 poses again with the pharmacophore resulted in 2894 compounds. These were divided into three 252 clusters, depending on the functional group placed in the hydrophilic pocket (tetrazoles, carboxylates, 253 sulfonamides) and inspected by eye. Finally, 31 compounds were selected for hit validation (Table 2) . 254
Most of the selected chemotypes carried an anionic group, mainly a carboxylic group or its bioisostere, 255 the tetrazole ring. Candidates were predicted to orient the anionic side of their moiety in the carboxylic 256 [a] Assays were performed in duplicate (errors were less than 5%) with CENTA as reporter substrate (100 μM, km 70 μM). Kinetic were monitored at 25° by following the absorbance variation at λ = 405 nm. [b] If no IC50 has been measured, percent inhibition at the highest tested concentration is given in parentheses. For example, > 0.50 (26 %) implies that the highest concentration tested was 0.50 mM; at this concentration, the enzyme was inhibited by 26 %. Therefore, IC50> 0.50 mM. When % Inhibition was below 10% No Inibition (NI) is reported in table.
[c] Assays were run after 10' incubation of the inhibitor with KPC-2. Reaction was started by the addition of CENTA.
262
Hit Evaluation
263
The majority of the selected candidates were fragment-like as defined by the "rule of three" [14] . Thus, 264 potencies in the high micromolar to millimolar range were expected. Unfortunately, the required high 265 concentrations for ligand testing could not always be achieved due to solubility issues which might have 266 resulted false negatives after testing. However, some of the tested molecules inhibited the hydrolytic 267 activity of KPC-2 with millimolar potency. Among those, compounds 9a and 11a were the most 268 promising compounds with micromolar affinities (IC50 of 0.15 and 0.036 mM, translating to ligand 269 efficiencies (LE) of 0.38 and 0.28 kcal/mol/non-hydrogen atom, respectively; Table 2 ) and were thus 270 further investigated. 271
Compound 9a was predicted to place its carboxylate group in proximity of the catalytic Ser70, in the 272 carboxylic acid binding site mentioned above, forming hydrogen bond interactions with the side chains 273 corresponding to amino acids Ser130, Thr235 and Thr237 (Fig. 6 ). Thr 237 in KPC-2 is known to be 274 
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For compound 9a binding affinity and mode of inhibition was determined by using gradient 291 concentrations of CENTA. Fitting of the obtained data showed that compound 9a behaves as a 292 competitive inhibitor with a determined Ki of 112.0 µM (Fig. 7) . Its binding affinity was also determined 293 towards other class A β-lactamases (IC50 vs CTX-M9 160 µM). For this compound aggregating behavior 294 was also excluded by dynamic light scattering experiment (data not shown) [40] . Compound 9a with its 295 fragment-like characteristic (MW 208.21, determined Ki 112.0 µM, LE 0.38 kcal/mol/non-hydrogen 296 atom) exerts an interesting activity vs KPC2-2 and represents a very promising molecule to be directed 297 to hit to lead optimization. 298 bioisostere of the carboxylic group, was predicted to lie in the hydrophilic pocket formed by Thr235, 303
Thr237, Ser130 and Ser70, driving the binding of the inhibitor in KPC-2 active site (Fig. 8) . The phenyl 304 ring attached to the tetrazole was predicted to be sandwiched between the Trp105 side with a distance 305 compatible with weak hydrophobic interactions and the backbone of Thr237. The amide group of 11a 306 was oriented in the canonical site delimited by Asn132, Asn170 and in a further distance Glu166 where 307 the R1 amide side chain of β-lactams is known to bind. However, the amine linker and the second phenyl 308 ring in 11a were not predicted to form any specific interactions with the protein, except for the amide 309 nitrogen contacting the backbone of Thr237. The distal fluoro-benzene ring was oriented at the entrance 310 of the active site against two hydrophobic patches, one defined by Leu167, closer, and the other by the 311 backbone of Asn170, a residue critical for carbapenemase activity. 312 
313
Based on the predicted binding mode, the tetrazole group of 11a seemed to be crucial for affinity. (Table  314 1). Moreover, while the proximal ring appeared to be involved in specific interactions, the amide group 315 and the distal ring did not contact efficaciously the protein. Based on predicted binding mode, chemical 316 size, synthetic accessibility for a rapid structural optimization and ligand efficacy compound 11a was 317 directed to chemical synthesis development to improve its affinity and to investigate target binding 318 requirements for optimal inhibitor-enzyme interaction. 319
Hit derivatization and evaluation 320
In order to improve the binding affinity of 11a, the compound was subjected to a hit optimization 321 program. Therefore, the phenyl-tetrazole moiety, that seemed to strongly drive the binding, was retained 322 unaltered, whereas structural modifications on the linker and on the distal aromatic ring were introduced 323 20 in order to explore and maximize the interactions with the pocket formed by Asn132, Asn170 and 324 Leu167 (Fig. 6 ). Because the amide linker does not contact efficaciously the protein we chose to replace 325 it with a sulfonamide (Fig. 9 ). We meant to target residues proximal to the opening of the active site 326 while investigating the potentiality for sulfonamide derivatives. Further, we explored different substitutions on the sulfonamide linker to probe binding interactions. 340
Substituents with different electronic and steric properties (i.e. halogens, nitro, sulfonamide, carboxylic 341 acid, methyl, acetamide, amino groups) were inserted in the different position of the aromatic ring. In 342 addition, the benzene ring was replaced by heterocyclic or extended benzofused systems such as 343 benzimidazole, quinazolinone, naphthalene, or quinolone ring. Based on the availability of compound 344 or building blocks, 6 compounds (1b-6b) were synthesized and 8 compounds (7b-14b) were purchased 345 to test our hypothesis ( Table 3 ). The fourteen new compounds were tested in vivo vs clinical strains 346 overproducing KPC-2 to evaluate their ability to restore bacteria susceptibility to carbapenem 347 meropenem (Table 4) . 348 349 22 [a] Assays were performed in duplicate (errors were less than 5%) with nitrocefin (114.28 μM, Km 36 μM) as 350 reporter substrate Kinetic were monitored at 25° by following the absorbance variation at λ = 485 nm. [b] If no IC50 351 has been measured, percent inhibition at the highest tested concentration is given in parentheses. For example, > 352 1.0 (37 %) implies that the highest concentration tested was 1.0 mM; at this concentration, the enzyme was 353 inhibited by 37 % and IC50> 1.0 mM. When % Inhibition was below 10% No Inhibition (NI) is reported in table.
355 356
Compounds 1b-6b were synthesized in high yield (75-95% yield) and purity (>95%) through direct 357 reaction of 3-(1H-tetrazol-5-yl) aniline and the appropriate sulfonyl chloride in dichloromethane at room 358 temperature for 3 hours (Fig. 11) . 359 360 Figure 11 . Reagents and conditions. a) aryl-sulfonyl chloride (1.2 eq.), pyridine (3 eq.), dry DCM, N2, r.t, 3 h, 75-95% yield.
